Q: Is there money to be made investing in pot?
A: Legalizing marijuana is a trend that's taking hold in the U.S. But despite what investors might think about the development, and if it's good for society, many are looking ways to profit from the trend.
So far, the stock market isn't a great place to play this development. A vast majority of the marijuana companies that have shares that can be bought and sold are penny stocks. Most of the stocks, ranging from GreenGro Technologies to Medical Marijuana, Hemp and Growlife, trade on the OTC Bulletin Board marketplace for less than a dollar a share. These companies do not have to meet any kind of listing standards, such as having a market value of a certain level or have investor safeguards such as an independent board of directors.
Best Transportation Companies To Buy Right Now: Opko Health Inc(OPK)
OPKO Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. It provides a range of solutions, including molecular diagnostics tests, proprietary pharmaceuticals, and vaccines to diagnose, treat, and prevent neurological disorders, infectious diseases, oncology, and ophthalmologic diseases. The company offers molecular diagnostic platform technology for the rapid identification of molecules or immunobiomarkers; Alzheimer?s test for Alzheimer?s diagnostic; and protein-based influenza vaccines to provide multi-season and multi-strain protection against various influenza virus strains, such as seasonal influenza strains, as well as global influenza pandemic strains which include swine flu, and avian flu. It also offers Oligonucleotide Therapeutics for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and oligosaccharide for asthma and chronic obstructive pulmonary diseases. In addition, the company provides Rolapitant, a potent and antagonist; neurokinin-1, which has completed Phase II clinical trials for prevention of chemotherapy induced nausea and vomiting, and post-operative induced nausea and vomiting; and SCH 900978 that has completed Phase II clinical trials for chronic cough. Further, it offers bevasiranib, a drug candidate for the treatment of Wet AMD; and develops Aquashunt, a shunt to be used in the treatment of glaucoma. Additionally, the company involves in the development, commercialization, and sale of ophthalmic diagnostic and imaging systems, and instrumentation products. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Advisors' Opinion:- [By GuruFocus]
Opko Health Inc. (OPK): CEO & Chairman, Director, 10% Owner Phillip Md Et Al Frost Bought 42,700 Shares
CEO & Chairman, Director, 10% Owner of Opko Health, Inc. (OPK) Phillip Md Et Al Frost bought 42,700 shares during the past week at an average price of $10.74. Opko Health, Inc. has a market cap of $4.33 billion; its shares were traded at around $10.74 with and P/S ratio of 39.84.
- [By Roberto Pedone]
Another healthcare player that insiders are jumping into here is Opko Health (OPK), which is a multi-national pharmaceutical and diagnostics company. Insiders are buying this stock into big time strength, since shares are up 76% in 2013.
Opko Health has a market cap of $3.4 billion and an enterprise value of $3.5 billion. This stock trades at a premium valuation, with a price-to-sales of 38.01 and a price-to-book at 4.01. Its estimated growth rate for this year is -218.2%. This is not a cash-rich company, since the total cash position on its balance sheet is $180.84 million and its total debt is $226.74 million.
The CEO just bought 19,400 shares, or about $171,000 worth of stock, at $8.79 to $8.90 per share. The same CEO also just bought 13,000 shares, or about $117,000 worth of stock, at $8.99 to $9.04 per share.
From a technical perspective, OPK is currently trending above its 200-day moving average and below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares falling from its high of $11.64 to its recent low of $8.17 a share. During that downtrend, shares of OPK have been making mostly lower highs and lower lows, which is bearish technical price action.
If you're in the bull camp on OPK, then I would look for long-biased trades as long as this stock is trending above its 200-day at $8.31 or above more key support at $8.17, and then once it breaks out above some near-term overhead resistance at $9.20 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 5.53 million shares. If that breakout hits soon, then OPK will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day of $10.06 a share to $11.64 a share.
- [By GuruFocus]
Opko Health, Inc. (OPK): CEO & Chairman, 10% Owner Phillip Md Et Al Frost Bought 686,000 Shares
CEO & Chairman, 10% Owner of Opko Health, Inc. (OPK) Phillip Md Et Al Frost bought 686,000 shares during the past week at an average price of $7.93. Opko Health, Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. Opko Health, Inc. has a market cap of $3.24 billion; its shares were traded at around $7.93 with and P/S ratio of 28.01.
Top 5 Diversified Bank Companies To Watch For 2014: Standard Pacific Corp(SPF)
Standard Pacific Corp. operates as a diversified builder of single-family attached and detached homes in the United States. It constructs homes targeting various homebuyers primarily move-up buyers in metropolitan markets in California, Florida, the Carolinas, Texas, Arizona, Colorado, and Nevada. The company also provides mortgage financing services to its homebuyers; and title examination services to its Texas homebuyers. As of December 31, 2011, it owned or controlled 26,444 homesites and had 166 active selling communities. Standard Pacific Corp. was founded in 1965 and is headquartered in Irvine, California.
Advisors' Opinion:- [By Sally Jones]
Standard Pacific Corp. (SPF): Reduced
Up 19% over 12 months, Standard Pacific Corp., a residential construction company, has a market cap of $2.27 billion. The current share price is around $8.18. Shares trade at a P/E of 5.70. The company does not pay a dividend.
- [By Erika Janowicz]
Compass Point analyst Wilkes Graham updated his housing forecast:
Graham increased assumed ROI's to 9% on average from 7%. Reduced targeted sector price/ book from $190% to 170%. Expects 20-30% growth in starts and new home sales in 2012 and 2013 to stabilize in 2014 and on at approximately 10%. For covered builders, the analyst lowered estimates by 8% and lowered price targets by 10%. Compass Point expects 10% annual growth in single family starts and new home sales and 2-5% pricing growth. Downgraded DR Horton Inc. (NYSE: DHI) from Buy to Neutral and KB Home (NYSE: KBH) from Neutral to Sell. DR Horton's and KB Home's PT was lowered from $23.50 to $20.00 and from $17.50 to $14.00, respectively. Graham reiterated a Buy rating on Ryland Group Inc. (NYSE: RYL) and Standard Pacific Corp. (NYSE: SPF). The analyst raised the PT on Ryland from $50.00 to $50.50 and lowered the PT on Standard Pacific from $10.00 to $9.50. Compass Point reiterated a Neutral rating on Beazer Homes USA Inc. (NYSE: BZH), Hovnanian Enterprises Inc. (NYSE: HOV), Lennar Corp. (NYSE: LEN), PulteGroup, Inc. (NYSE: PHM), and Toll Brothers Inc. (NYSE: TOL). The price target for Beazer and Hovnanian was raised from $15.50 to $24.00 and $5.00 to $5.75, respectively. Graham lowered the PT for Lennar, Pulte, and Toll to $34.50, $17.00, and $31.00.This Week's Data
Top 5 Diversified Bank Companies To Watch For 2014: Chelsea Therapeutics International Ltd.(CHTP)
Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutic products for the treatment of various human diseases. It is involved in developing Droxidopa, a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with primary autonomic failure and falls related to NOH in Parkinson?s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, adult attention deficit hyperactivity disorder, chronic fatigue syndrome, and freezing of gait in PD and down syndrome. The company intends to market its Droxidopa drug under the Northera brand name. It also engages in developing a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn?s disease, ankylosing spondylitis, uveitis, psoriatic arthritis, inflammatory bowel disease, cancer, and other immunological disorders. The company?s molecule products include a portfolio of metabolically inert antifolate molecules consisting of CH-1504 and CH-4051, which are orally available molecules with anti-inflammatory, autoimmune, and anti-tumor properties that inhibit various key enzymes required for cell proliferation; and a portfolio of dihydroorotate dehydrogenase, known as the I-3D portfolio, for applications in autoimmune diseases and transplantation. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina.
Advisors' Opinion:- [By Jon C. Ogg]
Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is finding a serious victory from its hypotension drug. Shares hit a 52-week high — make that a three-year high — after the company confirmed an accelerated FDA approval of its Northera for the treatment of low blood pressure, following FDA panel backing just last month.
- [By John Udovich]
The biotech roller-coaster continues for investors into 2014 with small cap Chelsea Therapeutics International Ltd (NASDAQ: CHTP) set to more than double when the market opens today, meaning its time to take a closer look at what in the world is going on with the stocks plus take a closer look at the performance of biotech peers like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
Top 5 Diversified Bank Companies To Watch For 2014: China Biologic Products Inc.(CBPO)
China Biologic Products, Inc., a biopharmaceutical company, through its subsidiaries, engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People?s Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also offers Human Hepatitis B Immunoglobulin for the prevention of measles and contagious hepatitis; Human Immunoglobulin and Human Immunoglobulin for Intravenous Injection products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides Injection that is used in the treatment of various original and sec ondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides Human Rabies Immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; Human Tetanus Immunoglobulin for the prevention and therapy of tetanus; and Placenta Polypeptide that is used for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia caused by various reasons, as well as assists in postoperative heating. The company?s products under development comprise Human Prothrombin Complex Concentrate; Human Coagulation Factor VIII; Human Hepatitis B Immunoglobulin (PH4) for Intravenous Injection; Human Fibrinogen; Varicella Hyperimmune Globulins; and Human Immunoglobulin for Intravenous Injection. The company is based in Beijing, the People's Republic of China.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Healthcare sector moved up 0.39 percent, with Keryx Biopharmaceuticals (NASDAQ: KERX) moving up 15 percent to gain the top spot. Top gainers in the sector included China Biologic Products (NASDAQ: CBPO), with shares up 7.4 percent, and Laboratory Corp. of America Holdings (NYSE: LH), with shares up 5.5 percent. - [By Jake L'Ecuyer]
Leading and Lagging Sectors
Healthcare sector moved up 0.39 percent, with Keryx Biopharmaceuticals (NASDAQ: KERX) moving up 15 percent to gain the top spot. Top gainers in the sector included China Biologic Products (NASDAQ: CBPO), with shares up 7.4 percent, and Laboratory Corp. of America Holdings (NYSE: LH), with shares up 5.5 percent.
No comments:
Post a Comment